Budipine
Budipine.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 1-tert-butyl-4,4-diphenylpiperidine[1]
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.055.494 Edit this at Wikidata
Chemical and physical data
FormulaC21H27N
Molar mass293.454 g·mol−1
3D model (JSmol)
  • c1(ccccc1)C3(c2ccccc2)CCN(C(C)(C)C)CC3
  • InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3 checkY
  • Key:QIHLUZAFSSMXHQ-UHFFFAOYSA-N checkY
  (verify)

Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease.[2][3][1]

While its exact mechanism of action is not well characterized,[2] it is believed to be an NMDA receptor antagonist,[4][5] but also promoting the synthesis of dopamine.[6]

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[6][7]

See also

References

  1. ^ Martndale: The Complete Drug Reference, 35th Ed.
  2. ^ a b Heinz Reichmann (October 2006). "Budipine in Parkinson's tremor". Journal of the Neurological Sciences. 248 (1–2): 53–55. doi:10.1016/j.jns.2006.05.039. PMID 16784759. S2CID 21540225.
  3. ^ H. Przuntek; T. Müller (1999). Clinical efficacy of budipine in Parkinson's disease. Journal of Neural Transmission. Supplementum. Vol. 56. pp. 75–82. doi:10.1007/978-3-7091-6360-3_3. ISBN 978-3-211-83275-2. PMID 10370903.
  4. ^ Kornhuber J., Herr B., Thome J., Riederer P. (1995). "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". Journal of Neural Transmission. Supplementum. 46: 127–133. PMID 8821048.((cite journal)): CS1 maint: multiple names: authors list (link)
  5. ^ Gene C. Palmer (September 2001). "Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies". Current Drug Targets. 2 (3): 241–271. doi:10.2174/1389450013348335. PMID 11554551.
  6. ^ a b Przuntek H, Bittkau S, Bliesath H, et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.
  7. ^ Jenny C.E. Owen; Peter S. Whitton (October 2006). "Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats". Brain Research. 1117 (1): 206–212. doi:10.1016/j.brainres.2006.07.039. PMID 16996043. S2CID 29177107.